多发性硬化症中的葡萄糖类-1受体激动剂:治疗前景,挑战和未来方向
Afsaneh Shirani1,2, Olaf Stuve3,4,5
1Saint Luke's Marion Bloch Neuroscience Institute, Kansas City, MO, USA.
Expert opinion on investigational drugs
|November 6, 2025
概括
基于临床前和早期临床数据,葡萄糖类-1受体激活剂 (GLP-1RAs) 对多发性硬化症 (MS) 的神经保护和复髓化有希望. 需要进一步的研究来证实它们在多发性硬化症患者中的疾病修饰作用.
科学领域:
- 神经科学是一个神经科学.
- 内分泌学 在内分泌学.
- 免疫学 免疫学 免疫学
背景情况:
- 类似葡萄糖-1受体激动剂 (GLP-1RAs) 已被批准用于治疗2型糖尿病,肥胖和其他疾病.
- 新出现的证据表明,与多发性硬化症 (MS) 相关的潜在神经保护和复髓化特性.
研究的目的:
- 审查GLP-1RAs作为MS重用疗法的潜力.
- 综合临床前和临床证据,确定障碍,并建议未来的研究方向.
主要方法:
- 在实验性自身免疫脑膜炎和毒素诱导的脱髓化模型中对临床前研究的审查.
- 对患有多发性硬化和更广泛的糖尿病队列的人类早期观察数据的分析.
- 评估潜在的作用机制,包括抗氧化作用,轴突保护和质激活调节.
主要成果:
- 临床前模型显示GLP-1RAs可以降低氧化压力,保护轴突,抑制神经炎症,并可能促进复髓化.
- 早期人类数据表明GLP-1RA在MS患者中耐受性良好,在不加剧疾病的情况下提供代谢益处.
- 糖尿病患者群体的观察数据暗示了神经功能障碍和痴呆症发病率的减少.
结论:
- GLP-1RAs在MS中显示出重要的临床前和早期临床承诺,用于神经保护.
- 目前尚缺少关于MS疾病修饰功效的明确证据.
- 富含生物标志物的机制性试验对于克服实际障碍和确认GLP-1RAs在改变MS轨迹方面的治疗潜力至关重要.
更多相关视频
相关概念视频
Glucagon-like Receptor Agonists
828
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
828
Direct-Acting Cholinergic Agonists: Therapeutic Uses
1.5K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.5K
Microorganisms in Medicine and Therapeutics
922
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
922
Myasthenia Gravis: Overview and Treatment
2.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.8K
Oral Hypoglycemic Agents: Glinides
577
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
577
Insulin: The Receptor and Signaling Pathways
2.7K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
2.7K


